These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 2908873

  • 21. Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension.
    García-Pagán JC, Feu F, Navasa M, Bru C, Ruiz del Arbol L, Bosch J, Rodés J.
    J Hepatol; 1990 Sep; 11(2):189-95. PubMed ID: 2123914
    [Abstract] [Full Text] [Related]

  • 22. [The effect of molsidomine on portal and cardiac hemodynamics in liver cirrhosis].
    Hüppe D, Jäger D, Tromm A, Tunn S, Barmeyer J, May B.
    Dtsch Med Wochenschr; 1991 May 31; 116(22):841-5. PubMed ID: 2036943
    [Abstract] [Full Text] [Related]

  • 23. Serotonin blockade in conscious, unrestrained cirrhotic dogs with portal hypertension.
    Mastaï R, Rocheleau B, Huet PM.
    Hepatology; 1989 Feb 31; 9(2):265-8. PubMed ID: 2492251
    [Abstract] [Full Text] [Related]

  • 24. A randomized multicenter double-blind comparison of urapidil and ketanserin in hypertensive patients after coronary artery surgery.
    van der Stroom JG, van Wezel HB, Langemeijer JJ, Korsten HH, Kooyman J, van der Starre PJ, Kal JE, Porsius M, van den Ende R, van Zwieten PA.
    J Cardiothorac Vasc Anesth; 1997 Oct 31; 11(6):729-36. PubMed ID: 9327314
    [Abstract] [Full Text] [Related]

  • 25. Short- and long-term hemodynamic response to octreotide in portal hypertensive patients: a double-blind, controlled study.
    Zironi G, Rossi C, Siringo S, Galaverni C, Gaiani S, Piscaglia F, Bolondi L.
    Liver; 1996 Aug 31; 16(4):225-34. PubMed ID: 8877991
    [Abstract] [Full Text] [Related]

  • 26. Hemodynamic effect of propranolol on portal hypertension in patients with HBsAg-positive cirrhosis.
    Kong CW, Lay CS, Tsai YT, Lee SD, Lai KH, Lo KJ, Chiang BN.
    Dig Dis Sci; 1986 Dec 31; 31(12):1303-6. PubMed ID: 3803132
    [Abstract] [Full Text] [Related]

  • 27. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis.
    Garcia-Pagán JC, Navasa M, Bosch J, Bru C, Pizcueta P, Rodés J.
    Hepatology; 1990 Feb 31; 11(2):230-8. PubMed ID: 2307401
    [Abstract] [Full Text] [Related]

  • 28. Effect of intraportal nitroglycerin on portosystemic hemodynamics in patients with cirrhosis: comparison with i.v. route.
    Iwao T, Toyonaga A, Sumino M, Takagi K, Ohkubo K, Inoue R, Tanikawa K.
    J Clin Gastroenterol; 1991 Aug 31; 13(4):424-31. PubMed ID: 1918848
    [Abstract] [Full Text] [Related]

  • 29. [Effect of a serotonin S2 receptor antagonist on portal hypertension due to cirrhosis. Preliminary results of a heart and liver hemodynamic study].
    Deflandre J, Pirotte J, Etienne M, Carlier J.
    Ann Gastroenterol Hepatol (Paris); 1988 Aug 31; 24(3):103-5. PubMed ID: 3400992
    [Abstract] [Full Text] [Related]

  • 30. 48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study.
    Ludwig D, Schädel S, Brüning A, Schiefer B, Stange EF.
    Dig Dis Sci; 2000 May 31; 45(5):1019-27. PubMed ID: 10795771
    [Abstract] [Full Text] [Related]

  • 31. Haemodynamic effects of molsidomine and propranolol in patients with cirrhosis.
    Combis JM, Vinel JP, Badia P, Barange K, Payen JL, Combis F, Desmorat H, Pascal JP.
    Br J Clin Pharmacol; 1996 May 31; 41(5):409-13. PubMed ID: 8735682
    [Abstract] [Full Text] [Related]

  • 32. Oral administration of clonidine in patients with alcoholic cirrhosis. Hemodynamic and liver function effects.
    Albillos A, Bañares R, Barrios C, Clemente G, Rossi I, Escartin P, Bosch J.
    Gastroenterology; 1992 Jan 31; 102(1):248-54. PubMed ID: 1727758
    [Abstract] [Full Text] [Related]

  • 33. Comparison of the effects of a cardioselective and a nonselective beta-blocker on portal hypertension in patients with cirrhosis.
    Hillon P, Lebrec D, Muńoz C, Jungers M, Goldfarb G, Benhamou JP.
    Hepatology; 1982 Jan 31; 2(5):528-31. PubMed ID: 7118065
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new beta-blocker with nitrovasodilating properties, in patients with portal hypertension due to cirrhosis. A comparative study with propranolol.
    Aramaki T, Sekiyama T, Katsuta Y, Kurokawa H, Komeichi H, Tsutsui H, Terada H, Ohsuga M, Satomura K, Okumura H.
    J Hepatol; 1992 May 31; 15(1-2):48-53. PubMed ID: 1354676
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation.
    Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Cavasin L, Gatta A.
    Aliment Pharmacol Ther; 2005 Sep 01; 22(5):433-9. PubMed ID: 16128681
    [Abstract] [Full Text] [Related]

  • 39. Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis.
    Møller S, Brinch K, Henriksen JH, Becker U.
    J Hepatol; 1997 May 01; 26(5):1026-33. PubMed ID: 9186833
    [Abstract] [Full Text] [Related]

  • 40. Hemodynamic effects of acute administration of furosemide in patients with cirrhosis receiving beta-adrenergic antagonists.
    Sogni P, Soupison T, Moreau R, Le Moine O, Bacq Y, Hadengue A, Lebrec D.
    J Hepatol; 1994 Apr 01; 20(4):548-52. PubMed ID: 7914215
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.